328 related articles for article (PubMed ID: 33001518)
1. Antifungal susceptibility profile and molecular identification of Cyp51C mutations in clinical and environmental isolates of Aspergillus flavus from Argentina.
Hermida-Alava K; Brito Devoto T; Sautua F; Gordó M; Scandiani M; Formento N; Luque A; Carmona M; Cuestas ML
Mycoses; 2021 Jan; 64(1):95-101. PubMed ID: 33001518
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
3. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
Al-Wathiqi F; Ahmad S; Khan Z
BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
[TBL] [Abstract][Full Text] [Related]
4. Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in
Rivero-Menendez O; Soto-Debran JC; Medina N; Lucio J; Mellado E; Alastruey-Izquierdo A
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285229
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen.
Khodavaisy S; Badali H; Hashemi SJ; Aala F; Nazeri M; Nouripour-Sisakht S; Sorkherizi MS; Amirizad K; Aslani N; Rezaie S
J Mycol Med; 2016 Jun; 26(2):116-121. PubMed ID: 26948143
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of Voriconazole Resistance in Clinical and Environmental Isolates of Aspergillus flavus and Investigation into the Role of Multidrug Efflux Pumps.
Paul RA; Rudramurthy SM; Dhaliwal M; Singh P; Ghosh AK; Kaur H; Varma S; Agarwal R; Chakrabarti A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126956
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India.
Sharma C; Kumar R; Kumar N; Masih A; Gupta D; Chowdhary A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311090
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of triazole-resistant Aspergillus fumigatus sensu stricto in an Argentinean cohort of patients with cystic fibrosis.
Brito Devoto T; Hermida-Alva K; Posse G; Finquelievich JL; García-Effrón G; Cuestas ML
Mycoses; 2020 Sep; 63(9):937-941. PubMed ID: 32648614
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.
Mello E; Posteraro B; Vella A; De Carolis E; Torelli R; D'Inzeo T; Verweij PE; Sanguinetti M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416538
[TBL] [Abstract][Full Text] [Related]
11. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
Espinel-Ingroff A; Diekema DJ; Fothergill A; Johnson E; Pelaez T; Pfaller MA; Rinaldi MG; Canton E; Turnidge J
J Clin Microbiol; 2010 Sep; 48(9):3251-7. PubMed ID: 20592159
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
14. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
[TBL] [Abstract][Full Text] [Related]
15.
Talbot JJ; Frisvad JC; Meis JF; Hagen F; Verweij PE; Hibbs DE; Lai F; Groundwater PW; Samson RA; Kidd SE; Barrs VR; Houbraken J
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451501
[TBL] [Abstract][Full Text] [Related]
16. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis.
Liu W; Sun Y; Chen W; Liu W; Wan Z; Bu D; Li R
Antimicrob Agents Chemother; 2012 May; 56(5):2598-603. PubMed ID: 22314539
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
Gregson L; Goodwin J; Johnson A; McEntee L; Moore CB; Richardson M; Hope WW; Howard SJ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5778-80. PubMed ID: 24041890
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole resistance genes in Aspergillus flavus clinical isolates.
Zaini F; Lotfali E; Fattahi A; Siddig E; Farahyar S; Kouhsari E; Saffari M
J Mycol Med; 2020 Jun; 30(2):100953. PubMed ID: 32362445
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
